Compare S & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | S | GKOS |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 2021 | 2015 |
| Metric | S | GKOS |
|---|---|---|
| Price | $17.03 | $139.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 12 |
| Target Price | $19.28 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 6.7M | 997.9K |
| Earning Date | 05-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,001,278,000.00 | $507,442,000.00 |
| Revenue This Year | $22.84 | $23.32 |
| Revenue Next Year | $17.32 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 21.89 | ★ 32.33 |
| 52 Week Low | $11.81 | $73.16 |
| 52 Week High | $21.40 | $148.11 |
| Indicator | S | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 61.05 |
| Support Level | $16.28 | $130.04 |
| Resistance Level | $17.18 | $147.43 |
| Average True Range (ATR) | 0.69 | 5.14 |
| MACD | 0.18 | 1.82 |
| Stochastic Oscillator | 90.22 | 77.50 |
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.